Progranulin overproduction due to Fli-1 deficiency contributes to the resistance of dermal fibroblasts to tumor necrosis factor in systemic sclerosis

Arthritis and Rheumatology

Volumn 67, Issue 12, 2015, Pages 3245-3255

  Ichimura, Yohei ^a   Asano, Yoshihide ^a   Akamata, Kaname ^a   Noda, Shinji ^a   Taniguchi, Takashi ^a   Takahashi, Takehiro ^a   Toyama, Tetsuo ^a   Tada, Yayoi ^a   Sugaya, Makoto ^a   Sato, Shinichi ^a   Kadono, Takafumi ^a  

^a UNIVERSITY OF TOKYO   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

C REACTIVE PROTEIN; PROGRANULIN; TRANSCRIPTION FACTOR FLI 1; TUMOR NECROSIS FACTOR; GRN PROTEIN, HUMAN; GRN PROTEIN, MOUSE; MESSENGER RNA; SIGNAL PEPTIDE;

ADULT; ANIMAL EXPERIMENT; ARTICLE; CONTROLLED STUDY; DERMATITIS; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; FIBROBLAST; GENE EXPRESSION; GENE SILENCING; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; IN VIVO STUDY; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; MOUSE; NONHUMAN; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SCLERODERMA; SKIN MANIFESTATION; SYSTEMIC SCLEROSIS; UPREGULATION; WILD TYPE; AGED; ANIMAL; CASE CONTROL STUDY; CYTOLOGY; DERMIS; DIFFUSE SCLERODERMA; DRUG EFFECTS; GENE EXPRESSION REGULATION; GENETICS; METABOLISM; SKIN;

AGED; ANIMALS; CASE-CONTROL STUDIES; DERMIS; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; FIBROBLASTS; GENE EXPRESSION REGULATION; GENE KNOCKDOWN TECHNIQUES; HUMANS; INTERCELLULAR SIGNALING PEPTIDES AND PROTEINS; MALE; MICE; MIDDLE AGED; PROTO-ONCOGENE PROTEIN C-FLI-1; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; SCLERODERMA, DIFFUSE; SCLERODERMA, SYSTEMIC; SKIN; TUMOR NECROSIS FACTOR-ALPHA; UP-REGULATION;

EID: 84948439929     PISSN: 23265191     EISSN: 23265205     Source Type: Journal    
DOI: 10.1002/art.39312     Document Type: Article

References (49)

1. Abraham DJ, Krieg T, Distler J, Distler O., Overview of pathogenesis of systemic sclerosis. Rheumatology (Oxford) 2009; 48 Suppl 3: iii3-7.
2. Varga J, Whitfield ML., Transforming growth factor-β in systemic sclerosis (scleroderma). Front Biosci (Schol Ed) 2009; 1: 226-35.
3. Asano Y., Future treatments in systemic sclerosis. J Dermatol 2010; 37: 54-70.
4. Jian J, Konopka J, Liu C., Insights into the role of progranulin in immunity, infection, and inflammation. J Leukoc Biol 2013; 93: 199-208.
5. He Z, Ong CH, Halper J, Bateman A., Progranulin is a mediator of the wound response. Nat Med 2003; 9: 225-9.
6. Ong CH, Bateman A., Progranulin (granulin-epithelin precursor, PC-cell derived growth factor, acrogranin) in proliferation and tumorigenesis. Histol Histopathol 2003; 18: 1275-88.
7. He Z, Bateman A., Progranulin (granulin-epithelin precursor, PC-cell-derived growth factor, acrogranin) mediates tissue repair and tumorigenesis. J Mol Med (Berl) 2003; 81: 600-12.
8. Cenik B, Sephton CF, Kutluk Cenik B, Herz J, Yu G., Progranulin: a proteolytically processed protein at the crossroads of inflammation and neurodegeneration. J Biol Chem 2012; 287: 32298-306.
9. Tang W, Lu Y, Tian QY, Zhang Y, Guo FJ, Liu GY, et al., The growth factor progranulin binds to TNF receptors and is therapeutic against inflammatory arthritis in mice. Science 2011; 332: 478-84.
10. Park B, Buti L, Lee S, Matsuwaki T, Spooner E, Brinkmann MM, et al., Granulin is a soluble cofactor for Toll-like receptor 9 signaling. Immunity 2011; 34: 505-13.
11. Liu CJ., Progranulin: a promising therapeutic target for rheumatoid arthritis. FEBS Lett 2011; 585: 3675-80.
12. Solis-Herruzo JA, Brenner DA, Chojkier M., Tumor necrosis factor α inhibits collagen gene transcription and collagen synthesis in cultured human fibroblasts. J Biol Chem 1988; 263: 5841-5.
13. Kahari VM, Chen YQ, Su MW, Ramirez F, Uitto J., Tumor necrosis factor-α and interferon-γ suppress the activation of human type I collagen gene expression by transforming growth factor-β1: evidence for two distinct mechanisms of inhibition at the transcriptional and posttranscriptional levels. J Clin Invest 1990; 86: 1489-95.
14. Verrecchia F, Pessah M, Atfi A, Mauviel A., Tumor necrosis factor-α inhibits transforming growth factor-β/Smad signaling in human dermal fibroblasts via AP-1 activation. J Biol Chem 2000; 275: 30226-31.
15. Yamane K, Ihn H, Asano Y, Jinnin M, Tamaki K., Antagonistic effects of TNF-α on TGF-β signaling through down-regulation of TGF-β receptor type II in human dermal fibroblasts. J Immunol 2003; 171: 3855-62.
16. Gruschwitz MS, Vieth G., Up-regulation of class II major histocompatibility complex and intercellular adhesion molecule 1 expression on scleroderma fibroblasts and endothelial cells by interferon-γ and tumor necrosis factor α in the early disease stage. Arthritis Rheum 1997; 40: 540-50.
17. Koch AE, Kronfeld-Harrington LB, Szekanecz Z, Cho MM, Haines GK, Harlow LA, et al., In situ expression of cytokines and cellular adhesion molecules in the skin of patients with systemic sclerosis: their role in early and late disease. Pathobiology 1993; 61: 239-46.
18. Yoshizaki A, Iwata Y, Komura K, Ogawa F, Hara T, Muroi E, et al., CD19 regulates skin and lung fibrosis via Toll-like receptor signaling in a model of bleomycin-induced scleroderma. Am J Pathol 2008; 172: 1650-63.
19. Spyropoulos DD, Pharr PN, Lavenburg KR, Jackers P, Papas TS, Ogawa M, et al., Hemorrhage, impaired hematopoiesis, and lethality in mouse embryos carrying a targeted disruption of the Fli1 transcription factor. Mol Cell Biol 2000; 20: 5643-52.
20. Asano Y, Ihn H, Yamane K, Kubo M, Tamaki K., Impaired Smad7-Smurf-mediated negative regulation of TGF-β signaling in scleroderma fibroblasts. J Clin Invest 2004; 113: 253-64.
21. Asano Y, Stawski L, Hant F, Highland K, Silver R, Szalai G, et al., Endothelial Fli1 deficiency impairs vascular homeostasis: a role in scleroderma vasculopathy. Am J Pathol 2010; 176: 1983-98.
22. Asano Y, Ihn H, Yamane K, Kubo M, Tamaki K., Increased expression levels of integrin αVβ5 on scleroderma fibroblasts. Am J Pathol 2004; 164: 1275-92.
23. Distler JH, Jungel A, Huber LC, Schulze-Horsel U, Zwerina J, Gay RE, et al., Imatinib mesylate reduces production of extracellular matrix and prevents development of experimental dermal fibrosis. Arthritis Rheum 2007; 56: 311-22.
24. LeRoy EC, Black C, Fleischmajer R, Jablonska S, Krieg T, Medsger TA Jr, et al., Scleroderma (systemic sclerosis): classification, subsets, and pathogenesis. J Rheumatol 1988; 15: 202-5.
25. Van den Hoogen F, Khanna D, Fransen J, Johnson SR, Baron M, Tyndall A, et al., 2013 classification criteria for systemic sclerosis: an American College of Rheumatology/European League Against Rheumatism collaborative initiative. Arthritis Rheum 2013; 65: 2737-47.
26. Kubo M, Czuwara-Ladykowska J, Moussa O, Markiewicz M, Smith E, Silver RM, et al., Persistent down-regulation of Fli1, a suppressor of collagen transcription, in fibrotic scleroderma skin. Am J Pathol 2003; 163: 571-81.
27. Asano Y, Czuwara J, Trojanowska M., Transforming growth factor-β regulates DNA binding activity of transcription factor Fli1 by p300/CREB-binding protein-associated factor-dependent acetylation. J Biol Chem 2007; 282: 34672-83.
28. Asano Y, Trojanowska M., Phosphorylation of Fli1 at threonine 312 by protein kinase C δ promotes its interaction with p300/CREB-binding protein-associated factor and subsequent acetylation in response to transforming growth factor β. Mol Cell Biol 2009; 29: 1882-94.
29. Asano Y, Markiewicz M, Kubo M, Szalai G, Watson DK, Trojanowska M., Transcription factor Fli1 regulates collagen fibrillogenesis in mouse skin. Mol Cell Biol 2009; 29: 425-34.
30. Nakerakanti SS, Kapanadze B, Yamasaki M, Markiewicz M, Trojanowska M., Fli1 and Ets1 have distinct roles in connective tissue growth factor/CCN2 gene regulation and induction of the profibrotic gene program. J Biol Chem 2006; 281: 25259-69.
31. Mauviel A, Heino J, Kahari VM, Hartmann DJ, Loyau G, Pujol JP, et al., Comparative effects of interleukin-1 and tumor necrosis factor-α on collagen production and corresponding procollagen mRNA levels in human dermal fibroblasts. J Invest Dermatol 1991; 96: 243-9.
32. Chizzolini C, Parel Y, De Luca C, Tyndall A, Akesson A, Scheja A, et al., Systemic sclerosis Th2 cells inhibit collagen production by dermal fibroblasts via membrane-associated tumor necrosis factor α. Arthritis Rheum 2003; 48: 2593-604.
33. Guerra RR, Kriazhev L, Hernandez-Blazquez FJ, Bateman A., Progranulin is a stress-response factor in fibroblasts subjected to hypoxia and acidosis. Growth Factors 2007; 25: 280-5.
34. Santiago B, Galindo M, Rivero M, Pablos JL., Decreased susceptibility to Fas-induced apoptosis of systemic sclerosis dermal fibroblasts. Arthritis Rheum 2001; 44: 1667-76.
35. Jelaska A, Korn JH., Role of apoptosis and transforming growth factor β1 in fibroblast selection and activation in systemic sclerosis. Arthritis Rheum 2000; 43: 2230-9.
36. Kim JY, Kwok SK, Hur KH, Kim HJ, Kim NS, Yoo SA, et al., Up-regulated macrophage migration inhibitory factor protects apoptosis of dermal fibroblasts in patients with systemic sclerosis. Clin Exp Immunol 2008; 152: 328-35.
37. Chizzolini C, Rezzonico R, Ribbens C, Burger D, Wollheim FA, Dayer JM., Inhibition of type I collagen production by dermal fibroblasts upon contact with activated T cells: different sensitivity to inhibition between systemic sclerosis and control fibroblasts. Arthritis Rheum 1998; 41: 2039-47.
38. Shirasaki F, Makhluf HA, LeRoy C, Watson DK, Trojanowska M., Ets transcription factors cooperate with Sp1 to activate the human tenascin-C promoter. Oncogene 1999; 18: 7755-64.
39. Czuwara-Ladykowska J, Sementchenko VI, Watson DK, Trojanowska M., Ets1 is an effector of the transforming growth factor β (TGF-β) signaling pathway and an antagonist of the profibrotic effects of TGF-β. J Biol Chem 2002; 277: 20399-408.
40. Wang Y, Fan PS, Kahaleh B., Association between enhanced type I collagen expression and epigenetic repression of the FLI1 gene in scleroderma fibroblasts. Arthritis Rheum 2006; 54: 2271-9.
41. Noda S, Asano Y, Akamata K, Aozasa N, Taniguchi T, Takahashi T, et al., A possible contribution of altered cathepsin B expression to the development of skin sclerosis and vasculopathy in systemic sclerosis. PLoS One 2012; 7: e32272.
42. Noda S, Asano Y, Takahashi T, Akamata K, Aozasa N, Taniguchi T, et al., Decreased cathepsin V expression due to Fli1 deficiency contributes to the development of dermal fibrosis and proliferative vasculopathy in systemic sclerosis. Rheumatology (Oxford) 2013; 52: 790-9.
43. Ichimura Y, Asano Y, Akamata K, Takahashi T, Noda S, Taniguchi T, et al., Fli1 deficiency contributes to the suppression of endothelial CXCL5 expression in systemic sclerosis. Arch Dermatol Res 2014; 306: 331-8.
44. Saigusa R, Asano Y, Taniguchi T, Yamashita T, Takahashi T, Ichimura Y, et al., A possible contribution of endothelial CCN1 downregulation due to Fli1 deficiency to the development of digital ulcers in systemic sclerosis. Exp Dermatol 2015; 24: 127-32.
45. Akamata K, Asano Y, Taniguchi T, Yamashita T, Saigusa R, Nakamura K, et al., Increased expression of chemerin in endothelial cells due to Fli1 deficiency may contribute to the development of digital ulcers in systemic sclerosis. Rheumatology (Oxford) 2015; 54: 1308-16.
46. Takahashi T, Asano Y, Noda S, Aozasa N, Akamata K, Taniguchi T, et al., A possible contribution of lipocalin-2 to the development of dermal fibrosis, pulmonary vascular involvement, and renal dysfunction in systemic sclerosis. Br J Dermatol 2015. E-pub ahead of print.
47. Noda S, Asano Y, Nishimura S, Taniguchi T, Fujiu K, Manabe I, et al., Simultaneous downregulation of KLF5 and Fli1 is a key feature underlying systemic sclerosis. Nat Commun 2014; 5: 5797.
48. Taniguchi T, Asano Y, Akamata K, Noda S, Takahashi T, Ichimura Y, et al., Fibrosis, vascular activation, and immune abnormalities resembling systemic sclerosis in bleomycin-treated Fli-1-haploinsufficient mice. Arthritis Rheumatol 2015; 67: 517-26.
49. Duan H, Fleming J, Pritchard DK, Amon LM, Xue J, Arnett HA, et al., Combined analysis of monocyte and lymphocyte messenger RNA expression with serum protein profiles in patients with scleroderma. Arthritis Rheum 2008; 58: 1465-74.